XenoPort unveils disappointing data for acid reflux drug

12/2/2008 | Reuters · Bloomberg

XenoPort reported midstage trial results showing that XP19986, a treatment for gastroesophageal reflux disease, did not demonstrate a significant difference versus placebo in decreasing heartburn. The company said it intends to conduct further studies after finding that the drug worked in patients who benefited at least partially from proton pump inhibitors.

View Full Article in:

Reuters · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA